Find Clinical Trials | Cedars-Sinai

157 results found

Prostate

NRG, NRG-GU010, Ph 3, Open Label, Prostate, RT vs. RT + ADT vs. RT + ADT + Darolutamide

1.1 Primary Objectives: 1.1.1 De-Intensification Study: To determine whether men with National Comprehensive Cancer Network (NCCN) unfavorable intermediate risk (UIR) prostate cancer and lower Decipher genomic risk (Decipher score < 0.40) treated with RT alone instead of ...

Breast, Colon, Esophagus, Kidney, Lung, Melanoma, Ovary

Shionogi, 2023P2411(aCCeleR8-001), Ph1b/2,Open,Advanced Solid Tumors,S-531011 +/- Pembrolizumab

Primary: -To evaluate the safety and tolerability of S-531011 and to determine the MTD and/or RP2D of S-531011. Secondary: - To evaluate the preliminary antitumor activity of S-531011 per RECIST version 1.1a. - To characterize the PK profile ...

Brain and Nervous System

Primary CNS Lymphoma: Phase I Trial of Methotrexate, Rituximab, Lenalidomide, and Nivolumab

The purpose of this study is to determine whether the drugs rituximab, methotrexate, lenalidomide, and nivolumab can be safely combined for treatment of primary CNS lymphoma. Researchers also want to learn which dose is the ...

Lung Cancer, Non-small cell

Osimertinib and Carotuximab in Advanced, EGFR-Mutated Non-Small Cell Lung Cancer

The purpose of this study is to examine the safety and effectiveness of an experimental combination therapy of osimertinib (standard drug) with carotuximab (investigational study drug) in patients who are diagnosed with EGFR-mutated, non-small cell ...

Leukemia, other

Inotuzumab Ozogamicin in Children and Young Adults With Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia

This study focuses on children and young adults who have been diagnosed with B-acute lymphoblastic leukemia (B-ALL) that is either unresponsive to therapy (refractory) or has come back after treatment (relapsed). B-ALL is a cancer ...